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Background
Monitoring the safety of therapies is of paramount
importance in protecting patients from harm and
enabling risk-benefit assessment. The recording and
reporting of measures of efficacy has received consider-
able attention and while by no means perfect, has
advanced further than the parallel assessment of harm.
The stimulus for this study came from a commissioned
effectiveness and cost-effectiveness review of treatments
for neuropathic pain in patients (the CEAN study) [1].
C E A Nn o t e dt h a tt h ec o m p l e t e n e s so fa d v e r s ee v e n t
(AE) reporting varied between trials and some expert
opinion was required where primary data were insuffi-
cient for modeling cost-effectiveness. Further, clinicians
indicated that trials sometimes failed to provide ade-
quate information for clinical decision-making and
informing patients.
Objectives
To describe how AE data are collected and reported. To
explore results post-2004 (when regulatory requirements
regarding collection and reporting of AEs for RCTs
were in place)
Methods
Relevant CEAN study publications (RCTs of anticonvul-
sants and antidepressants for post herpetic neuralgia
and painful diabetic neuropathy) with separable primary
data on impact on pain. Items for data extraction were
generated using recommendations set out in CONSORT
2004 [2]. Additional information extracted sought to
determine the criteria used by authors to select AEs for
reporting (e.g. significant differences), the mode of col-
lection (e.g. observation or questionnaire) and how they
were collected (e.g. passively, actively (prompted). Dou-
ble data extraction was performed.
Results
53 publications were included, 12 were published post
2004. Key results are presented in Tables 1 and 2. A
subset of the recommendations laid out in CONSORT
2004 were not adhered to by any of the publications.
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Table 1
All (N=53) n (%) Post-2004 (N=12) n (%)
Reported total number who withdrew & withdrew due to AE 48 (91) 12 (100%)
Reported that grading for AEs were assigned 30 (57) 9 (75)
Reported mode of collection (e.g. questionnaire, patient reported, observation) 23 (43) 5 (42)
Distinction between severe/life threatening AEs and those that were not. 29 (55) 11 (92)
Reported the dictionary used for coding AEs 1 (1.9) 0 (0.0)
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reproduction in any medium, provided the original work is properly cited.The collection method impacts on the number of AEs
reported by patients and this was poorly reported by the
majority of trials. The criteria used by authors for
reporting AEs varied substantially across publications.
Conclusion
Synthesis of AE data across studies is hampered by the
lack of information on collection methods and by arbi-
trary heterogeneous criteria used by authors for select-
ing AEs to be reported. In order to improve the
usefulness of AE data reported by publications, validated
methods for collection need to be developed, and core
AEs for reporting need to be agreed. Online journal
supplements can be utilised to overcome journal space
limitations. The issues highlighted by this case study are
likely to be relevant for AE reporting in RCTs in gen-
eral, although solutions will likely need to be tailored to
specific therapeutic-disease areas.
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Table 2 Criteria used to select AEs for reporting
Criteria n (%)
Most frequent AEs 17 (32)
All AE’s that occurred 17 (32)
Other 6 (11)
A pre-specified list of AEs 5 (9.4)
Unclear 3 (5.7)
Not applicable as no AE reported 3 (5.7)
Any AE with sig diff between treatment groups 2 (3.8)
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